NOAA Seafood Inspections Program had planned 1 May end to export certifications for fish oil supplements before granting 90-day extension as it talks with FDA about administering the program.

Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics. 

National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.

The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.